Several G-protein-coupled receptors contain cysteine residues in the C-terminal tail that may modulate receptor function. In this work we analysed the substitution of Cys 438 by alanine in the glucagon-like peptide-1 (GLP-1) receptor (GLPR), which led to a threefold decrease in cAMP production, although endocytosis and cellular redistribution of GLP-1 receptor agonist-induced processes were unaffected. Additionally, cysteine residues in the C-terminal tail of several G-protein-coupled receptors were found to act as substrates for palmitoylation, which might modify the access of protein kinases to this region. 
Introduction
Glucagon-like peptide-1(7-36)amide (GLP-1) is an intestinal peptide synthesised in L-cells. It is also produced in the brain (Jin et al. 1988 , Kreymann et al. 1989 , where it exerts some effects on neurotransmitter release from selected brain nuclei (Mora et al. 1992 , Calvo et al. 1995 and produces an inhibitory effect on food and water intake (Navarro et al. 1996 , Tang-Christensen 1996 , Turton et al. 1996 . Subcutaneous administration of GLP-1(7-36)amide also elicits a reduction in food and water intake (Rodriguez de Fonseca et al. 2000) . Similar results were found in human subjects when the peptide was administered peripherally (Gutzwiller et al. 1999) . Administered subcutaneously, the peptide could be transported into the brain through the choroid plexus, which has a high density of GLP-1 receptors (GLPR) (Alvarez et al. 1996) , or by blood-brain barrier-free organs, such as the subfornical organ and the area postrema (Orskov et al. 1996) . It has also been suggested that this peptide acts as a neurotrophic factor. GLP-1 receptors are expressed at high levels in glial cells after mechanical injury (Chowen et al. 1999 ) and it has recently been shown that GLP-1(7-36)amide can promote the proliferation and differentiation of PC12 cells (Perry et al. 2002) .
GLP-1(7-36)amide also has a potent effect on glucosedependent insulin secretion (Kreymann et al. 1987 , Weir et al. 1989 , and it also increases arterial blood pressure, heart rate (Barragán et al. 1994 (Barragán et al. , 1996 , and lung surfactant synthesis (Benito et al. 1998 , Vara et al. 2001 .
The effects of GLP-1(7-36)amide are mediated through a specific G-protein-coupled receptor (Thorens 1992 , Wei & Mojsov 1995 , Alvarez et al. 1996 and its signalling on target cells is dependent on activation of the adenylate cyclase pathway (Thorens 1992 . In this context, the third intracellular cytoplasmic loop is involved in coupling to G proteins and activation of the adenylyl cyclase system (Takhar et al. 1996) . Desensitisation of the GLP-1 receptor has been correlated with C-terminal tail phosphorylation. Homologous desensitisation produced by GLP-1(7-36)amide induces the phosphorylation of three serine doublets located at positions 441/442, 444/445 and 451/452 and decreases maximum cAMP production by 20% (Widmann et al. 1997) . Heterologous desensitisation of the GLP-1 receptor by protein kinase C (PKC) is correlated with the phosphorylation of four serine doublets located at positions 431/432, 441/442, 444/445 and 451/452. Activation of PKC by phorbol esters also decreases maximum cAMP production by 30% (Widmann et al. 1996a,b) , and the levels of phosphorylation induced by GLP-1 and phorbol esters are additive (Widmann et al. 1996b) . Phosphorylation of the three serine doublets, Ser 441/442 , Ser 444/445 and Ser 451/452 , at the cytoplasmic tail after agonist binding is related to receptor endocytosis (Widmann et al. 1997) . Agonist-promoted phosphorylation of the G-protein-coupled receptors increases the affinity of -arrestins and these act as a clathrin adaptor protein in the internalisation process (Goodman et al. 1996) .
Most G-protein-coupled receptors have one or two cysteine residues in the carboxyl-terminal cytoplasmic tail, and palmitoylation of these cysteines has been reported for several members of this family of receptors (Bouvier et al. 1995a ,b, Morello & Bouvier 1996 . The palmitate tail anchors the cytoplasmic tail of the receptor into the plasma membrane to create a fourth intracellular loop, allowing a reversible and dynamic regulation (Bouvier et al. 1995a) .
The aim of this study was to investigate whether cysteine 438 is a site of acylation and the function of Cys 438 in signal transduction through GLP-1 receptors.
Materials and Methods

Mutagenesis of the GLP-1 receptor
A HindIII-XbaI fragment of the rat GLP-1 receptor cDNA (Thorens 1992 ) was subcloned into PUC 18. Site-directed mutagenesis of cysteine 438 was accomplished using the Transformer Site-directed Mutagenesis kit from Clontech (Palo Alto, CA, USA). Mutagenic primers were prepared: 5 CCCCTTAAGGCTCCCAC CAGC 3 to change Cys 438 to Ala and to create a BfrI restriction site, and 5 CCCCTTAAGTGTCCCACC AGC 3 to create only a BfrI restriction site at nucleotide 1322. A selection primer, 5 GTGTATCTTATGCC AAGTACG 3 , to eliminate a unique NdeI restriction site in the vector was also used. Clones BfrI/Ala 438 and BfrI were selected and mutations were confirmed by sequencing using an automated LKB ALF DNA sequencer (Amersham Pharmacia Biotech, Barcelona, Spain). HindIII-XbaI mutant cDNA was then cloned into the expression vector to create pcDNA3-GLPR A 438 and pcDNA3 GLPR BfrI.
For substitution of amino acids Ser 431/432 by alanine, PCR site-directed mutagenesis was used, following standard procedures. The following primers were used: two flanking primers -GLPR-1 oligonucleotide, corresponding to nucleotides 969-993, and GLPR-2 oligonucleotide, corresponding to nucleotides 1384-1411 (Thorens 1992 /well) were washed with serumfree medium and incubated for 30 min at 37 C in KRH (118 mM NaCl, 5 mM KCl, 1·2 mM MgSO 4 , 2·5 mM CaCl 2 , 25 mM HEPES, pH 7·4) with 0·5% bovine serum albumin (BSA). Then, cells were chilled on ice, and 125 I-GLP-1(7-36)amide (0·1 nM) and unlabelled GLP-1(7-36)amide (0·0-500 nM) were added for at least 16 h at 4 C. Following this, cells were washed three times with cold medium and solubilised with 1 M NaOH. Nonspecific binding of 125 I-GLP-1(7-36)amide was estimated in the presence of 500 nM unlabelled ligand and this value was subtracted from the total binding values.
cAMP production assays cAMP levels were measured using the cAMP Biotrack enzyme immunoassay system (Amersham Biosciences, UK) following the manufacturer's instructions. Briefly, untransfected CHO cells and cells expressing wild-type and mutant GLP-1 receptors were grown in 12-well plates in F-12 medium supplemented with 5% FBS. CHO cells were washed and incubated in F-12 medium containing 0·1% FBS overnight. Cells were then washed with HBS medium (130 mM NaCl, 0·9 mM NaH 2 PO 4 , 0·8 mM MgSO 4 , 5·4 mM KCl, 1·8 mM CaCl 2 , 20 mM HEPES, pH 7·4, plus 25 mM glucose) and incubated in HBS containing 1 mM IBMX and 0·1% BSA in the presence or absence of different concentrations of GLP-1(7-36)amide (0·001-100 nM) for 8 min. Then, cells were washed with HBS, after which lysis buffer was added and immediately processed in the immunoassay. In parallel experiments, binding of 125 I-GLP-1(7-36)amide to cell surface receptors was determined at 4 C. The agonist stimulated cAMP production was normalised by 125 I-GLP-1(7-36)amide bound to cell surface receptors.
Internalisation of the GLP-1 receptor
The internalisation rate was measured as previously described (Alvarez et al. 1990) . Briefly, CHO cells were incubated in KRH (118 mM NaCl, 5 mM KCl, 1·2 mM MgSO 4 , 2·5 mM CaCl 2 , 25 mM HEPES, pH 7·4) with 0·5% BSA at 37 C for 30 min. Then, cells were incubated with 0·1 nM 125 I-GLP-1(7-36)amide, and 125 I-GLP-1(7-36)amide binding was determined at different times. Intracellular 125 I-GLP-1(7-36)amide was measured as cell-associated radioactivity resistant to acid wash by incubation of the cells for 3 min at 4 C with 50 mM NaCl, 150 mM glycine, pH 3·0. Cell surface-bound 125 I-GLP-1(7-36)amide was calculated by subtraction of the intracellularly bound 125 I-GLP-1(7-36)amide from the total binding.
Effect of metabolic inhibitors and hypertonic medium on the internalisation process
For metabolic depletion, CHO cells were washed twice with glucose-free HBS (140 mM NaCl, 20 mM HEPES, 1 mM CaCl 2 , 1 mM MgCl 2 , 10 mM KCl with 0·5% BSA) and incubated in the same buffer containing 20 mM 2-deoxyglucose and 10 mM sodium azide. Hypertonic treatment was performed as previously described (Heuser & Anderson 1989) . Briefly, cells were washed twice with HBS containing 0·45 M sucrose and incubated in the same medium for 30 min at 37 C. Then, 0·1 nM 125 I-GLP-1(7-36)amide was added and after 6 min incubation cell-associated radioactivity and acid wash-resistant radioactivity were measured as previously described.
Redistribution of cell surface GLP-1 receptors
CHO cells were seeded in 24-well plates and incubated with 10 nM GLP-1(7-36)amide for different times (3, 6, 10, 15, 30 and 60 min) . Then, the cells were washed at 0 C and subsequently incubated for 3 min at 0 C with 50 mM NaCl, 150 mM glycine, pH 3·0, to remove ligand bound to the cell surface, and washed with KRH containing 0·5% BSA. Cell surface receptors were then measured as described above.
Immunoprecipitation of tag-GLPR receptors
CHO cells expressing tag-GLPR wild-type or mutant receptors were seeded in 60 cm 2 dishes for metabolic labelling. The cells were transferred into culture media:
(1) methionine-free modified Eagle's medium containing 150 µCi/ml 35 S-methionine (Amersham Pharmacia Biotech) and (2) F-12 medium containing 1% fetal bovine serum (FBS) (GIBCO, Life Technologies, Paisley, UK) and 200 µCi/ml 3 H-palmitate (Dupont-NEN, Boston, MA, USA). The cells were then washed and solubilised in PBS containing 1% Triton X-100, 1% deoxycholate, 0·1% SDS, 0·5 M NaCl, 5 mM EDTA, 1 mM PMSF, 50 mM NaF, 5 mM Na 4 P 2 O 7 and 1 mM Na 3 VO 4 . The lysates were centrifuged at 10 000 g for 30 min and the supernatants were incubated with agarose-Streptavidin at room temperature for 30 min. After centrifugation, the supernatants were incubated for 60 min at room temperature with monoclonal anti-FLAG epitope M2-biotin conjugate antibody (SIGMA, Madrid, Spain) prebound to 50 µl agarose-Streptavidin or monoclonal anti-FLAG epitope M2-agarose (SIGMA). The immunoprecipitates were washed and resolved by SDS-PAGE and fluorography.
For purification of His-tagged GLP-1 receptors, crude membrane fractions of CHO cells expressing GLP-1 receptors were loaded into His micro spin columns (Amersham Biosciences Europe, Barcelona, Spain) previously incubated in the presence or absence of an excess of polyHis (30 µg/ml). Then, the columns were washed twice with phosphate/NaCl solution containing 20 mM imidazole and twice with phosphate/NaCl 60 mM imidazole and finally eluted with phosphate/NaCl solution containing 400 mM imidazole. Western blot analyses with anti-His antibody (Amersham Biosciences Europe) were performed following the manufacturer's instructions.
CHO cells expressing His-wild-type or mutant GLP-1 receptors were also labelled with 35 S-methionine or 3 Hpalmitate as described above. His-tagged GLP-1 receptors were purified using His micro spin columns and samples were resolved by SDS-PAGE and fluorography.
Data analysis
Data from competition experiments were analysed by non-linear regression with the GraphPad Prism computer program (GraphPad Software Inc., San Diego, CA, USA). Dissociation constants (K d ) and concentrations of receptor sites (B max ) were calculated from IC 50 values using the method of Cheng and Prusoff (1973) . Data are expressed as means S.E.M. Statistical comparisons were performed using the Student's t-test and Newman-Keuls test with at least three separate experiments performed in duplicate (*P<0·05 and **P<0·001).
Results
Effect of the mutation in Cys 438 on GLP-1 receptor binding
To analyse the role of Cys 438 located in the C-terminal domain of the GLP-1 receptor (Fig. 1 were substituted by alanine (Fig. 1 
Activation of adenylate cyclase
The binding of GLP-1(7-36)amide to its receptor produces activation of the adenylate cyclase pathway. Accordingly, we tested the effect of this peptide on the production of cAMP by cells transfected with the wildtype and mutant GLP-1 receptors. As shown in Fig. 3 , GLP-1(7-36)amide stimulated CHO cells expressing wild-type receptors in a dose-dependent manner; the EC 50 of GLP-1(7-36) amide was 0·09 0·03 nM, maximum stimulation (R max ) being observed at 10 nM of the agonist (Table 1) . CHO cells expressing mutant GLPR A 438 receptors showed a similar EC 50 0·05 0·016 nM value calculated from the dose-response curve (Fig. 3) . However, the mutant receptor revealed a 60-70% decreased efficacy as compared with wild-type receptors (Table 1) . Similar results were obtained using a pool of clones expressing the wild-type and mutant GLP-1 receptors.
Post-translational modifications of the GLP-1 receptor
To investigate post-translational modifications of the GLP-1 receptor by acylation, CHO cells expressing tagwild-type GLP-1 receptors were labelled with 35 Smethionine and 3 H-palmitic acid. The immunoprecipitates were analysed by non-reducing polyacrylamide gel electrophoresis and fluorography. The epitope-tagged GLP-1 receptors were not immunoprecipitated by anti-FLAG M2 monoclonal antibody or anti-FLAG M2 affinity gel, and hence we could not detect tag-GLP-1 receptors in cells labelled with 35 S-methionine. We therefore decided to use 6
His-tagged GLP-1 receptors. His-GLP-1 receptors were isolated using His micro spin columns. Western blot analysis using an anti-His antibody (Fig. 4) revealed the presence of a 65 kDa band in CHO cells expressing His-tagged wild-type and mutant Ala GLP-1 receptors. This band disappeared when the columns were previously saturated with polyHis. CHO cells expressing His-tagged wild-type and mutant GLP-1 receptors were metabolically labelled with 35 S-methionine and 3 H-palmitate. His-GLP-1 receptors were purified with His micro spin columns and subjected to SDS-PAGE and fluorography. As shown in Fig. 4 (Fig. 1) .
Effect of substitution of Ser 431/432 by alanine on adenylate cyclase activation
Substitution of Ser
431/432 by alanine in the wild-type receptor did not modify the potency and efficacy of such receptors in stimulating cAMP production (Fig. 3 , Table  1 ). By contrast, in cells expressing GLPR A 431/432/438 the EC 50 value of GLP-1(7-36)amide was similar to that of the wild-type, but the efficacy was three-to fourfold increased relative to the wild-type (Table 1) . Figure 5A shows that the substitution of Cys 438 or Ser 431/432 by alanine in the GLP-1 receptor did not were 0·198 0·005 min -1 , 0·217 0·006 min -1 , 0·18 0·014 min -1 and 0·22 0·015 min -1 respectively. The rate of endocytosis of GLP-1 receptors was also similar in a pool of clones expressing the wild-type and mutant GLP-1 receptors. The effects of metabolic inhibitors or hypertonic medium on the rate of endocytosis were also measured (Fig. 5B) . The rate of endocytosis was inhibited by 73-90% under both conditions after metabolic depletion and hypertonic treatment in cells expressing wild-type or mutant receptors.
Effect of the Cys 438 mutation and the substitution of Ser 431/432 by alanine on the rate of GLP-1 receptor endocytosis
Effect of agonist on the cellular redistribution of GLP-1 receptors
It has been reported that GLP-1 receptor recycling to the cell surface following agonist-induced endocytosis takes about 15 min and that a rapid rate of endocytosis produces a progressive decrease in the surface expression of GLP-1 receptors upon continuous exposure to the agonist.
The effect of pre-exposure to 10 nM GLP-1(7-36)amide on cell surface receptors was determined as a function of time, as shown in Fig. 5C . A rapid decrease in cell surface receptor numbers was observed in cells expressing wild-type and mutant GLP-1 receptors. In both cases, the number of cell surface receptors decreased during the first 15 min of agonist exposure, receptor numbers falling to 45-50% of the initial values. After longer times of exposure, the number of cell surface receptors decreased slowly to 36-27% in cells expressing wild-type and mutant receptors respectively.
Discussion
Here we report the results obtained following the replacement of Cys 438 by alanine in the rat GLP-1 receptor. The data obtained by us show that the GLP-1 receptor is palmitoylated and that substitution of Cys 438 by alanine prevented 3 H-palmitate incorporation to GLP-1 receptors. We do not have any information about the stoichiometry of GLP-1 receptor palmitoylation.
As compared with the wild-type receptor, the efficacy of mutant A 438 receptors in stimulating adenylate cyclase activity after GLP-1(7-36)amide treatment decreased approximately threefold. A decrease in cAMP production in cells expressing mutant GLPR A 438 receptors is consistent with the data reported for non-palmitoylated 2 adrenergic receptors (O'Dowd et al. 1989 ) and the D1 dopamine receptor (Jensen et al. 1995) . In our data, the differences in cAMP production are not correlated with a change in the agonist-affinity state of GLP- expressed low levels of receptors as compared with wildtype receptors. Thus, these findings cannot be related to the effect of palmitoylation or depalmitoylation.
It has been reported that the region involved in the coupling of GLP-1 receptors to G proteins is located in the third intracellular cytoplasmic loop (Takhar et al. 1996) and that C-terminal tail phosphorylation is involved in the desensitisation process. Nevertheless, a receptor lacking 33 amino acids of the C-terminal tail stimulates cAMP production at the same rate as wild-type receptors (Widmann et al. 1996a,b) . We also tested a truncated receptor lacking 27 amino acids of the C-terminal tail and this truncated form stimulated cAMP production at a similar rate to wild-type receptors, indicating that this region of the cytoplasmic tail is not necessary for the GLP-1 receptor/G protein interaction (our unpublished data).
Palmitoylation of cysteines in the carboxyl terminal tail of G-protein-coupled receptors anchors this receptor domain into the plasma membrane, forming a fourth intracellular loop. Substitution of Cys 438 in GLP-1 receptors abolishes 3 H-palmitate incorporation, which should produce a different conformational state of the carboxyl terminal tail and may affect the access of kinases to the cytoplasmic tail.
The cytoplasmic tail of GLPR also contains several phosphorylation sites reported to be necessary for the internalisation and desensitisation of GLP-1 receptors. Previous work using GLP-1 receptors revealed that PKC activation by phorbol esters produced phosphorylation of the four serine doublets in the intracytoplasmic tail: (Widmann et al. 1997) , and the receptor phosphorylation induced by homologous and heterologous desensitisation is additive (Widmann et al. 1996b) . The substitution of Cys 438 might regulate the access of protein kinases to such phosphorylation sites. Thus, the phosphorylation of a protein kinase A (PKA) site in the 2 -adrenergic receptor located downstream from the palmitoylated cysteine is also dependent on the state of palmitoylation of the receptor (Moffett et al. 1993 (Moffett et al. , 1996 . It has also been reported that mutations of the two Cys residues in the A 3 -adenosine receptor increase phosphorylation of the receptor independently of the presence of agonist (Palmer & Stiles 2000) . Palmitoylation of the vasopressin V 1a receptor also regulates phosphorylation, but in this case the reduction of [ 3 H]palmitate incorporation decreased the basal level of phosphorylation of mutant receptors (Hawtin et al. 2001) .
Since our data indicated that the rate of endocytosis was similar in wild-type and mutant receptors, and since it has been reported that phosphorylation of the three doublets Ser 441/442 , Ser 444/445 and Ser 451/452 is involved in this process, we next investigated the effect of the substitution of serines 431/432 by alanines in the wild-type and GLPR A 438 receptors. The substitution of Ser 431/432 by alanine did not modify the potency or efficacy of these receptors in stimulating adenylate cyclase. In contrast, substitution of these residues in GLPR A 438 receptors increased the efficacy in stimulating adenylate cyclase at concentrations higher than 1 nM GLP-1(7-36)amide.
The results obtained after the substitution of Ser 431/432 by alanine when Cys 438 is also absent suggest that the rate of phosphorylation of the other serine doublets in the cytoplasmic tail might also be affected. To confirm this hypothesis it would be necessary to analyse the effect of substitution of the other sites of phosphorylation involved in the desensitisation and internalisation of GLP-1 receptors. However, a synergistic action of kinases on other members of G-protein-coupled receptors, such as 2 -adrenergic receptors (Moffett et al. 2001) and A 3 -adenosine receptors (Palmer & Stiles 2000) , has been reported previously.
The effect of the substitution of Cys 438 by alanine on the endocytosis and recycling processes was also tested. The GLPR A 438 receptors did not show significant differences in the internalisation rate as compared with the wild-type GLP-1 receptor and, likewise, the number of cell surface receptors after agonist exposure decreased in the same way as in cells expressing the wild-type receptors. Substitution of Ser 431/432 by alanine in wild-type and GLPR A 438 did not modify either the rate of endocytosis or the number of cell surface receptors after exposure to 10 nM agonist. The effect of acid washing was similar in all clones used. Our results suggest that the substitution of Ser 431/432 or Cys 438 by Ala in the GLP-1 receptor does not modify the capacity of these receptors to interact with the components of the vesicular transport system.
We also studied the endocytosis pathway used by these receptors, testing the effect of hypertonic medium; we found that all wild-type and mutant GLPR A 438 , GLPR A 431/432 and GLPR A 431/432/438 receptors were mainly internalised through coated pits.
In conclusion, the substitution of Cys 438 in the cytoplasmic tail of GLP-1 receptors decreases the efficacy of adenylate cyclase stimulation promoted by agonist binding through these receptors. In addition, this residue is a site of acylation of GLP-1 receptors and might regulate the state of phosphorylation of the GLP-1 receptor, which modulates the desensitisation process. Nevertheless, further studies are required to confirm the latter hypothesis.
